Cinnarizine


Diphenylmethyl-piperazine calcium channel blocker / antihistamine

A diphenylmethyl-piperazine T-type calcium channel blocker with antihistamine activity; used for vertigo, motion sickness, and cerebrovascular disease.

Abstract

Cinnarizine (1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; CAS 298-57-7; molecular formula C26H28N2; molecular weight 368.52) is a diphenylmethyl-piperazine multi-target compound developed at Janssen and approved in many European and Asian markets in the 1970s. Mechanism: T-type voltage-gated calcium channel inhibition (cerebrovascular dilation, vestibular nerve effects), H1 antihistamine activity, and weak D2 dopamine receptor antagonism. The combined activity supports use in vestibular disorders, motion sickness, and cerebrovascular insufficiency. The D2 antagonism produces a small but real risk of extrapyramidal side effects (parkinsonism, tardive dyskinesia) with long-term use, particularly in elderly patients; this has limited use in some jurisdictions. Plasma half-life is approximately 4 hours. Approved for vertigo, motion sickness, and cerebrovascular disease in EU and Asia; not approved in the US. Used as a multi-target reference compound for vestibular pharmacology.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph